戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rder structure and endosomal location of the CpG oligonucleotide.
2  IL-12, and IL-6 was secreted in response to CpG oligonucleotide.
3 gins produced IFN-alpha when stimulated with CpG oligonucleotides.
4  respond to structurally distinct classes of CpG oligonucleotides.
5 he presence of agonistic Abs against CD40 or CpG oligonucleotides.
6 pG motifs abolished the protective effect of CpG oligonucleotides.
7  to explore the importance of the spacing of CpG oligonucleotides.
8 in response to cytosine-phosphate-guanosine (CpG) oligonucleotides.
9  receptor 9, and we found that the synthetic CpG oligonucleotide 2006 (CpG) reduced the frequency of
10 tes on the cell surface, where it recognizes CpG oligonucleotide 2006.
11 targeted co-delivery of antigen peptides and CpG oligonucleotides (a Toll-like receptor-9 agonist).
12                          We demonstrate that CpG oligonucleotides activate a TLR9-independent pathway
13 S) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909).
14 We show that siRNA synthetically linked to a CpG oligonucleotide agonist of toll-like receptor (TLR)9
15 c precursor cells isolated from human blood, CpG oligonucleotides alone were superior to GMCSF in pro
16                         H9-MSA combined with CpG oligonucleotide also induced potent responses.
17 g conventional Toll-like receptor 9 ligands (CpG oligonucleotides), although it could be demonstrated
18 lls enhances cell proliferation triggered by CpG oligonucleotides and decreases sensitivity to dexame
19                                              CpG oligonucleotides and imiquimod, prototypic drugs in
20 SF) for concentrating dendritic cells (DCs), CpG oligonucleotides, and a doxorubicin-iRGD conjugate e
21             In addition, preclinical data on CpG oligonucleotides appear to be encouraging, particula
22            The effects of both anti-CD40 and CpG oligonucleotides are dependent upon induction of IL-
23  MNs coated with Ova as a model allergen and CpG oligonucleotide as an adjuvant (MNs-CIT) into the sk
24  intracerebral deposition of TLR9-activating CpG oligonucleotides, but not following non-CpG oligonuc
25 h peptide and cytosine-guanine dinucleotide (CpG) oligonucleotide, but not control oligonucleotide, s
26 e have recently shown that the TLR9 agonists CpG oligonucleotides can be used for targeted siRNA deli
27  could also produce IFN-alpha in response to CpG oligonucleotides, consistent with the observations o
28                           Engaging TLR9 with CpG oligonucleotide contributes to the development of IL
29 zation and by adjuvants such as unmethylated CpG oligonucleotide (CpG) and LPS that induce T helper t
30  muramyl dipeptide (MDP), LPS, and a B-class CpG oligonucleotide (CpG-B), can substitute for gut flor
31                                    Synthetic CpG oligonucleotides (CpG DNA) are a relatively new clas
32                               Hypomethylated CpG oligonucleotides (CpG) are not only potent adjuvants
33 d stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastas
34 es adjuvanted by a robust formulation of the CpG oligonucleotide delivered in emulsion were superior
35 coproteins adjuvanted with MF59 containing a CpG oligonucleotide elicited strong CD4(+) T helper resp
36 ted that oropharyngeal delivery of synthetic CpG-oligonucleotides elicited minimal lung inflammation
37 e contention that repeated administration of CpG-oligonucleotides enhances the effect of peptide and
38                These findings suggest that a CpG oligonucleotide given intratumorally may increase th
39                            Compared with non-CpG oligonucleotides, i.v. treatment with CpG oligonucle
40 pairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemother
41 s a role for liver NK1.1(+) cells, IL-22 and CpG oligonucleotides in the induction of tolerance to is
42 ncodes Hv1, impaired mouse pDC activation by CpG oligonucleotides in vitro and in vivo, reducing IFN-
43 ident CLL cells and in cells stimulated with CpG oligonucleotides in vitro.
44  CpG oligonucleotides, but not following non-CpG oligonucleotide injection or after aseptic cryoinjur
45 eletion of SphK1 in pDCs mitigates uptake of CpG oligonucleotide ligands by TLR9 ligand.
46                             Three classes of CpG oligonucleotide ligands for Toll-like receptor (TLR)
47 pathway were functional, since class B and C CpG oligonucleotide ligands stimulated production of RAN
48               Remarkably, adjuvantation with CpG oligonucleotides markedly increased GC T(FH) and GC
49                            Immunostimulatory CpG oligonucleotides (ODN) activate cells that express T
50                                    Synthetic CpG oligonucleotides (ODN) have potent immunostimulatory
51                            Immunostimulatory CpG oligonucleotides (ODN) show promise as immune adjuva
52 se surface expression of CD80 in response to CpG oligonucleotides (ODN).
53 of functional nanodiamonds (fNDs) to deliver CpG oligonucleotides (ODNs) for sustained immunostimulat
54                            Administration of CpG oligonucleotide or cationic lipid 3beta-[N-(N',N'-di
55 st, poly I:C, but not by other TLR agonists, CpG oligonucleotide or Toxoplasma gondii antigen.
56  activated by exposure to LPS, nonmethylated CpG oligonucleotides, or CD40L.
57 on-CpG oligonucleotides, i.v. treatment with CpG oligonucleotides resulted in higher systemic concent
58 ced IL-10-secreting Treg with TLR9 agonists, CpG oligonucleotides, resulted in decreased IL-10 and IF
59 he efficiency of EBV B-CLL transformation of CpG oligonucleotide-stimulated cells by incubating patie
60               Vaccination of T1D mice with a CpG oligonucleotide TLR9 agonist (ODN 1585) enhances exp
61 polysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-depen
62 lpha secretion from pDCs and that inhibitory CpG oligonucleotide treatment diminished HSV-induced IFN
63 ated increase in memory development, as both CpG oligonucleotide treatment or cotransfer of wild-type
64 cytokine production and tumor necrosis after CpG-oligonucleotide treatment and deficient production o
65  blockade of the inhibitory receptor CD96 or CpG-oligonucleotide treatment.
66 d uninfected individuals to the TLR9 agonist CpG oligonucleotide type B (CpG-B) in the presence and a
67                     The protective effect of CpG oligonucleotides was observed in mice with either a